Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Blood (2024) 144 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2024-201373

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Blood (2024) 144 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2024-199742

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Leyre Bento, Fernando Martín Moro, Antonio Gutierrez, Ana Jiménez Ubieto, Alberto López, Blanca Sánchez González, Belén Navarro, Alicia Segura, Mireia Franch, Ana García-Noblejas, Eva Donato, Alejandro Martín García-Sancho, Beatriz De La Cruz, Alfonso Ortiz Algarra, Roberto Trelles-Martínez, Javier López, Carlos Grande, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2024-203615

Published: 2024

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Blood (2019) 134 (Supplement_1): 5249.

https://doi.org/10.1182/blood-2019-125921

Published: 2019

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.

Eva González-Barca, Miguel Canales, MD, PhD, María Jesús Vidal, Albert Oriol, Antonio Salar, Joan Bargay, Montse Cortés, Juan Coya, José Francisco Tomás, Andrés López, José Javier Sánchez, Eva Donato, Andrés Llorente, Secundino Ferrer, Dolores Caballero

Blood (2010) 116 (21): 2793.

https://doi.org/10.1182/blood.V116.21.2793.2793

Published: 2010

Journal Articles

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain.

Eva Gonzalez-Barca, Miguel Canales, Antonio Salar, Albert Oriol, María Jesús Vidal, Joan Bargay, Montse Cortés, J. Coya, Jose Francisco Tomas, Andrés López, José Javier Sánchez, Eva Donato, Andrés Llorente, Secundino Ferrer, Dolores Caballero

Blood (2009) 114 (22): 3692.

https://doi.org/10.1182/blood.V114.22.3692.3692

Published: 2009

Journal Articles

“Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study”.

F.J. Capote, Eva Gonzalez-Barca, Albert Oriol, MD, Antonio Romero-Aguilar, Angel Leon, F.J. Fernandez-Calvo, Elena Pérez-Ceballos, Eva Donato, Dolores Caballero, Jose Antonio Queizán, María Jesus Peñarrubia, MD, Luis Palomera, Julio Prieto, Pilar Giraldo, MD, Juan Bergua, MD

Blood (2009) 114 (22): 931.

https://doi.org/10.1182/blood.V114.22.931.931

Published: 2009

Journal Articles

Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome

Blood (2008) 112 (11): 2593.

https://doi.org/10.1182/blood.V112.11.2593.2593

Published: 2008

NARROW

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02)

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain.

“Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study”.

Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only